The Company and Summary of Significant Accounting Policies - Additional Information (Detail) - Litigation Status [Domain] $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015 USD ($) Customer application $ / shares	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) shares Customer application $ / shares	Jun. 30, 2014 USD ($)	Dec. 31, 2014 Customer
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$ 332,106	$ 289,100	$ 639,141	$ 534,086
Number of customers with significant accounts receivable | Customer	5		5		5
Percentage of gross accounts receivable	88.00%		88.00%		86.00%
Convertible Debt [Member]
Summary Of Significant Accounting Policies [Line Items]
Interest rate	1.875%	1.875%	1.875%	1.875%	1.875%
Number of shares issuable from exchangeable senior notes | shares			2.9
Debt conversion price (in dollars per share) | $ / shares	$ 199.77		$ 199.77
Express Scripts [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	70.00%		70.00%		66.00%
Idis Limited [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	8.00%		8.00%		11.00%
Xyrem [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$ 247,846	$ 191,366	$ 460,536	$ 351,744
Number of ANDAs filed by third parties | application	7		7
Xyrem [Member] | Sales Revenue, Product Line [Member] | Product Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net	74.60%		72.10%
Erwinaze And Erwinase [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales, net	$ 46,151	$ 47,869	$ 96,504	$ 94,789
Erwinaze And Erwinase [Member] | Sales Revenue, Product Line [Member] | Product Concentration Risk [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of product sales, net	13.90%		15.10%